Skip to content

Study of Welltang- a Cell Phone-based Diabetes Management Application's Effect on Blood Glucose Control

Study of Welltang- a Cell Phone-based Diabetes Management Application's Effect on Blood Glucose Control

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02313090
Enrollment
100
Registered
2014-12-09
Start date
2014-01-31
Completion date
2014-05-31
Last updated
2014-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

The aim was to assess the impact of a cell phone-based diabetes management application (Welltang) on HbA1c, blood glucose, lipids, physical activity, weight, and blood pressure during 3 months. And hypoglycemic events, the satisfaction of the patients with Boyibang, their diabetes knowledge and self-care behaviors were also evaluated.

Detailed description

At baseline, all patients completed the Diabetes Self- Care Behavior Questionnaire and a Diabetes Knowledge Survey. Health, medical and demographic history, height and weight, waist and hip circumferences, and blood pressure were recorded. HbA1c and low-density lipoprotein cholesterol (LDL-C) level were tested. All of these data were measured 3 months later at the conclusion of the study intervention.

Interventions

OTHERWelltang

The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians

Sponsors

First Affiliated Hospital of Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All diabetes, aged more than 18 years old. No limit for HbA1c was defined

Exclusion criteria

* patients have any severe complications such as end phase of diabetic nephropathy or proliferative retinopathy. patients who cannot use smart phone.

Design outcomes

Primary

MeasureTime frame
HbA1c3 months

Secondary

MeasureTime frame
blood pressure3 months
low density lipoprotein cholesterol3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026